Jais Rose Bjelke

Jais Rose Bjelke

Auto-generated profile, based on publicly available information

Jais Rose Bjelke

Global Research, Novo Nordisk A/S, 2760 Måløv, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KLKatrine S. Larsen
Katrine S. Larsen
HØHenrik Østergaard
Henrik Østergaard
OOOle H. Olsen
Ole H. Olsen
JBJais R. Bjelke
Jais R. Bjelke
WRWolfram Ruf
Wolfram Ruf
LPLars C. Petersen
Lars C. Petersen
The complex of factor VIIa (FVIIa) with tissue factor (TF) triggers coagulation by recognizing its macromolecular substrate factors IX (FIX) and X (FX) predominantly through extended exosite interactions. In addition, TF mediates unique cell-signaling properties in cancer, angiogenesis, and inflammation that involve proteolytic cleavage of protease-activated receptor 2 (PAR2). PAR2 is cleaved by FVIIa in the binary TF·FVIIa complex and by FXa in the ternary TF·FVIIa·FXa complex, but physiological roles of these signaling complexes are incompletely understood. In a screen of FVIIa protease domain mutants, three variants (Q40A, Q143N, and T151S) activated macromolecular coagulation substrates and supported signaling of the ternary TF·FVIIa-Xa complex normally but were severely impaired in binary TF·FVIIa·PAR2 signaling. The residues identified were located in the model-predicted S2′ pocket of FVIIa, and complementary PAR2 P2′ Leu-38 replacements demonstrated that the P2′ side chain was indeed crucial for PAR2 cleavage by TF·FVIIa. In addition, PAR2 was activated more efficiently by FVIIa T99Y, consistent with further contributions from the S2 subsite. The P2 residue preference of FVIIa and FXa predicted additional PAR2 mutants that were efficiently activated by TF·FVIIa but resistant to cleavage by the alternative PAR2 activator FXa. Thus, contrary to the paradigm of exosite-assisted cleavage of PAR1 by thrombin, the cofactor-associated protease FVIIa recognizes PAR2 predominantly by catalytic cleft interactions. Furthermore, the delineated molecular details of this substrate interaction enabled protein engineering of protease-selective PAR2 receptors that will aid further studies to dissect the roles of TF signaling complexes in vivo.

13 July 2007 in Biochemical Journal
Verified
Journal Article
Open access
KLKatrine S. Larsen
Katrine S. Larsen
HØHenrik Østergaard
Henrik Østergaard
JBJais R. Bjelke
Jais R. Bjelke
OOOle H. Olsen
Ole H. Olsen
HRHanne Borger Rasmussen
Hanne Borger Rasmussen
HSHenning R. Stennicke
Henning R. Stennicke
The remarkably high specificity of the coagulation proteases towards macromolecular substrates is provided by numerous interactions involving the catalytic groove and remote exosites. For FVIIa [activated FVII (Factor VII)], the principal initiator of coagulation via the extrinsic pathway, several exosites have been identified, whereas only little is known about the specificity dictated by the active-site architecture. In the present study, we have profiled the primary P4–P1 substrate specificity of FVIIa using positional scanning substrate combinatorial libraries and evaluated the role of the selective active site in defining specificity. Being a trypsin-like serine protease, FVIIa had P1 specificity exclusively towards arginine and lysine residues. In the S2 pocket, threonine, leucine, phenylalanine and valine residues were the most preferred amino acids. Both S3 and S4 appeared to be rather promiscuous, however, with some preference for aromatic amino acids at both positions. Interestingly, a significant degree of interdependence between the S3 and S4 was observed and, as a consequence, the optimal substrate for FVIIa could not be derived directly from a subsite-directed specificity screen. To evaluate the role of the active-site residues in defining specificity, a series of mutants of FVIIa were prepared at position 239 (position 99 in chymotrypsin), which is considered to be one of the most important residues for determining P2 specificity of the trypsin family members. This was confirmed for FVIIa by marked changes in primary substrate specificity and decreased rates of antithrombin III inhibition. Interestingly, these changes do not necessarily coincide with an altered ability to activate Factor X, demonstrating that inhibitor and macromolecular substrate selectivity may be engineered separately.

11 December 2006 in FEBS Letters
Verified
Journal Article
Closed access
JBJais R. Bjelke
Jais R. Bjelke
EPEgon Persson
Egon Persson
HRHanne Borger Rasmussen
Hanne Borger Rasmussen
BKBirthe Kragelund
Birthe Kragelund
OOOle H. Olsen
Ole H. Olsen

29 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CHCecilie Bo Hansen
Cecilie Bo Hansen
IJIda Jarlhelt
Ida Jarlhelt
LPLaura Pérez-Alós
Laura Pérez-Alós
LLLone Hummelshøj Landsy
Lone Hummelshøj Landsy
MLMette Loftager
Mette Loftager
MSMikkel-Ole Skjoedt
Mikkel-Ole Skjoedt
Globally, the COVID-19 pandemic has had extreme consequences for the healthcare system and calls for diagnostic tools to monitor and understand the transmission, pathogenesis and epidemiology, as well as to evaluate future vaccination strategies. Here we have developed novel flexible ELISA-based assays for specific detection of SARS-CoV-2 antibodies against the receptor-binding domain (RBD): An antigen sandwich-ELISA relevant for large population screening and three isotype-specific assays for in-depth diagnostics. Their performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infection, ranging from asymptomatic to critical cases. We mapped the antibody responses to different areas on protein N and S and showed that the IgM, A and G antibody responses against RBD are significantly correlated to the disease severity. These assays—and the data generated from them—are highly relevant for diagnostics and prognostics and contribute to the understanding of long-term COVID-19 immunity.

20 December 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
ABAmalie Carnbring Bonde
Amalie Carnbring Bonde
JLJacob Lund
Jacob Lund
JHJens Jacob Hansen
Jens Jacob Hansen
JWJakob Rahr Winther
Jakob Rahr Winther
PNPer Franklin Nielsen
Per Franklin Nielsen
JBJais Rose Bjelke
Jais Rose Bjelke

9 January 2026 in Protein Engineering, Design and Selection
Verified
Journal Article
Closed access
MMMie M Mortensen
Mie M Mortensen
SGSusanne N Grell
Susanne N Grell
TEThomas Egebjerg
Thomas Egebjerg
CYChe Yang
Che Yang
NLNikolai Lorenzen
Nikolai Lorenzen
JBJais R Bjelke
Jais R Bjelke
Antibody prodrugs represent a promising therapeutic format that provides advantages compared to conventional monoclonal antibody therapeutics. In this study, we engineered an antibody prodrug using an anti-P-selectin antibody as a model system, incorporating N-terminal heavy chain extensions comprising a linear P-selectin (CD62P) epitope for shielding, a thrombin-cleavable linker, and variable spacer in the linker. A prodrug antibody library was prepared comprising various N-terminal extensions of the heavy chain including an Ala-scan over the P-selectin epitope and the thrombin cleavage site sequence (50 variants in the library). The shielding library was thoroughly investigated for retained target binding kinetics and cleavage activation kinetics. Antibody prodrug variants achieving complete shielding of target binding to a completely open state were observed in the library (many orders of magnitude reduced binding based on surface plasmon resonance (SPR) kinetic measurement). Upon thrombin activation, the antibody prodrug variants obtained full target binding at low nM affinity. Thus, at such nM antibody prodrug concentrations, the liberated shielding extensions appeared to diffuse effectively away from the paratope upon cleavage based on SPR and fluorescence-activated cell sorting (FACS) analyses. Importantly, binding studies of variants of the linear epitope peptide alone showed many orders-of-difference in reduced binding compared to the fused extensions of the epitope sequence to the antibody prodrug. Comparison of the kinetic data with a structure model of the prodrug antibody reveals aspects of designing an optimal prodrug antibody that may have general applicability as a novel therapeutic format.